Shire Eyes Lifitegrast For Growth But Still Gets Dry Reception
The specialty pharma expressed confidence about the late-stage dry-eye drug lifitegrast at a Dec. 10 R&D day, but analysts remain wary about whether Shire can hit sales goals based on its current pipeline.
You may also be interested in...
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.